-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Hospital
-
Emergency department
-
SARS-CoV-2
-
Respiratory syncytial virus
-
Influenza virus
-
Adults (18-64 years)
-
Elderly (≥65 years)
-
Fragile population
-
Immunocompromised host
-
Hospital
-
Respiratory syncytial virus
-
Pharmacological intervention
-
Vaccination
-
Arexvy
-
Adults (18-64 years)
-
Elderly (≥65 years)
-
Fragile population
-
Immunocompromised host
-
Hospital
-
Respiratory syncytial virus
-
Pharmacological intervention
-
Vaccination
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Hospital
-
Intensive care unit
-
Respiratory syncytial virus
-
Blood sample
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Primary care
-
SARS-CoV-2
-
Respiratory syncytial virus
-
Influenza virus
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Infants (<1 year)
-
Children (1-11 years)
-
Adolescents (12-17 years)
-
Hospital
-
Non-hospital health centre
-
SARS-CoV-2
-
Respiratory syncytial virus
-
Influenza virus
-
Adenovirus
-
Rhinovirus
-
Parainfluenza Virus
-
Metapneumovirus
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Primary care
-
Respiratory syncytial virus
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Hospital
-
Outpatient clinic
-
Respiratory syncytial virus
-
Bordetella pertussis
-
Blood sample
-
Nasopharyngeal swab
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Hospital
-
SARS-CoV-2
-
Respiratory syncytial virus
-
Influenza virus
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Hospital
-
Respiratory syncytial virus
-
Adults (18-64 years)
-
General population
-
Elderly (≥65 years)
-
Hospital
-
Respiratory syncytial virus
-
Adults (18-64 years)
-
Elderly (≥65 years)
-
People at high risk of STIs
-
Men who have sex with men
-
PrEP users
-
Outpatient clinic
-
Monkeypox virus
-
Serum
-
Pharmacological intervention
-
Vaccination
-
MVA-BN